[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"depression--major-depressive-disorder\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:depression--major-depressive-disorder":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,44,57,85,118,148,175,203],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":4},"100053986","stress-management-and-meditative-movements-for-asian-americans-with-depression-and-physical-symptoms-100053986",false,"NCT07610928","Stress Management and Meditative Movements for Asian Americans With Depression and Physical Symptoms","Integrating the Stress Management and Resiliency Training (SMART) With Qigong\u002FTai Chi (QTC) to Develop a Holistic Treatment for Asian Americans With Depression and Distressing Somatic Symptoms","Inclusion Criteria:\n\n* Self-identify as being of Asian ethnicity\n* English language proficiency\n* Be ≥18 years of age\n* Satisfy DSM-5 criteria for MDD prior to the initiation of the study intervention, as determined by a clinical interview conducted by the Principal Investigator (PI) during screening using DSM-5 diagnostic criteria.\n* A baseline of the Patient-Reported Outcomes Measurement Information System (PROMIS) Depression score ≥ 16\n* A baseline score of PHQ-15 ≥10\n* Have not had Tai Chi\u002FQigong training\u002Fpractice or other forms of mind-body intervention (e.g. yoga, mindfulness training, muscle relaxation training, etc) more than once a week in the past 3 months\n* A total score 24 or higher in Mini-Mental Status Examination for cognitive ability (if the participant endorses a history of cognitive impairment).\n* Willing to keep any psychiatric medications and psychotherapy stable throughout the course of the study (from Week 0 baseline to Week 12 Follow-up)\n* Have access to a device (i.e., smartphone, iPad, personal computer) and a stable network to attend the online group sessions\n* Ability to perform daily physical activity\n\nExclusion Criteria:\n\n* Have a primary psychiatric diagnosis other than MDD\n* Any history of psychosis, mania, or impulsivity and difficulty relating to people and judged by the clinician not appropriate for group intervention\n* Active eating disorder or substance use disorder within the last 6 months\n* Any relevant medical conditions that may be the medical basis of depression including thyroid diseases, epilepsy, history of an abnormal EEG, severe head trauma, or stroke\n* Have serious uncontrolled medical conditions (e.g. poorly controlled diabetes, severe congestive heart failure), or other medical conditions that in the opinion of the investigators represents a risk to the subject, including presence of a pacemaker, cardiac arrhythmia, fever, weakness and hypotension, or vagal nerve stimulator\n* current active suicidal or self-injurious potential (i.e., PHQ-9 item 9 ≥1 and\u002For a positive response to C-SSRS screener items 3, 4, 5, or 6), and assessed by the clinician necessitating immediate treatment\n* Participant who are or who plan to receive confounding treatments (including treatment of endocrinopathies): use of antidepressants, complementary and alternative medical (CAM) treatments thought to have beneficial effects on mood, including St. John's Wort, S-Adenosyl methionine (SAMe), omega-3 fatty acids, light therapy, conventional psychotherapy, mind-body interventions (e.g. Qigong, mindfulness training, muscle relaxation training, etc.)\n* Electroconvulsive therapy (ECT) during the last year as these patients are often among the more refractory and are not optimal candidates for CAM\n* History of refractory to treatment with ≥3 failed antidepressant trials in current depressive episode\n* Participated in other depression-related clinical trials within the past 3 months\n* Antidepressant or psychiatric medications that are initiated less than 8 weeks or a dose change less than 4 weeks prior to screening visit\n* Psychotherapy that has been initiated within the past 3 months","ALL","18 Years",{"count":19,"type":20},70,"ESTIMATED","INTERVENTIONAL",[23],"NA","Many Asian Americans with depression also struggle with physical symptoms-such as pain, fatigue, or other forms of bodily discomfort-that occur at the same time. Right now, there is no proven treatment that effectively addresses both the depression and these physical symptoms together. This study will test whether it is practical, acceptable, and safe to combine the Stress Management and Resiliency Training (SMART) program with meditative movements for people who have both major depression and these distressing physical symptoms.",[26,27],"Depression \u002F Major Depressive Disorder","Mental Health (Depression)",[29,30,31],"Depression","Asian American","Somatic symptoms","NOT_YET_RECRUITING","2026-07-10",{"date":35,"type":36},"2026-07-13","ACTUAL",{"date":38,"type":20},"2026-08-15",{"date":40,"type":20},"2027-08-31",{"name":42,"class":43},"Massachusetts General Hospital","OTHER",{"id":45,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":46,"targetDuration":4,"studyType":21,"phases":47,"briefSummary":24,"conditions":48,"keywords":49,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":50,"lastUpdatePostDateStruct":51,"startDateStruct":53,"completionDateStruct":55,"leadSponsor":56,"locationsCount":4},"100638186",{"count":19,"type":20},[23],[26,27],[29,30,31],"2026-06-20",{"date":52,"type":36},"2026-06-25",{"date":54,"type":20},"2026-06-01",{"date":40,"type":20},{"name":42,"class":43},{"id":58,"slug":59,"hasResults":11,"nctId":60,"briefTitle":61,"officialTitle":61,"acronym":4,"eligibilityCriteria":62,"healthyVolunteers":11,"sex":63,"minAge":17,"maxAge":64,"enrollmentInfo":65,"targetDuration":4,"studyType":21,"phases":67,"briefSummary":68,"conditions":69,"keywords":71,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":84},"100642741","stronger-together-antenatal-depressive-symptoms---prevalence-and-digital-treatment-100642741","NCT07639164","Stronger Together: Antenatal Depressive Symptoms - Prevalence and Digital Treatment","Inclusion Criteria:\n\n* fluent in written and spoken Finnish or Swedish\n* access to computer or mobile phone with internet\n* between 12 and 22 weeks pregnant\n* screening and baseline score on the EPDS ≥10 points\n\nExclusion Criteria:\n\n* lifetime history of psychotic disorder (e.g. schizophrenia, schizoaffective disorder, bipolar disorder, psychotic depression)\n* active suicidal ideation\n* severe substance abuse or dependence\n* participates in another intervention study aiming at treating the symptoms of antenatal depression","FEMALE","55 Years",{"count":66,"type":20},1000,[23],"The main objective of the current research project is to evaluate the usability, satisfaction of the antenatal iCBT program including telephone coaching for antenatal and postnatal depressive symptoms and collect nationally representative data on population-based screening of antenatal depressive and anxiety symptoms. The overarching hypothesis is that iCBT, with easy access and affordability, is user friendly and well accepted. In addition to examining the treatment response by questionnaires, we will study the infant development comprehensively as well as potential physiological changes associated with antenatal depression or its treatment.",[26,70],"Antenatal Depression",[72,73,74],"Digital intervention","Cognitive Behaviour Therapy","Antenatal depression","2026-06-05",{"date":77,"type":36},"2026-06-10",{"date":79,"type":20},"2026-08-01",{"date":81,"type":20},"2030-12-30",{"name":83,"class":43},"University of Turku",1,{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":4,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":16,"minAge":92,"maxAge":93,"enrollmentInfo":94,"targetDuration":4,"studyType":21,"phases":96,"briefSummary":97,"conditions":98,"keywords":103,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":114,"leadSponsor":116,"locationsCount":84},"100640620","youth-suicide-prevention-cams-bi-vs-safety-planning-in-a-randomized-trial-100640620","NCT07628192","Youth Suicide Prevention: CAMS-BI vs. Safety Planning in a Randomized Trial","Innovating Suicide Preventative Care for Youth; A Randomized Trial of CAMS- BI Versus Stanley- Brown Safety Planning Intervention in Preventing Suicide Driven Readmission","Inclusion Criteria:\n\n* Adolescents aged 12-17 years.\n* Admitted to inpatient psychiatry for suicide attempt or active suicidal ideation.\n* English-speaking patient and parent\u002Fguardian.\n* Ability to understand and the willingness to sign a written informed assent document with a parent\u002Fguardian willing and able to sign a written informed consent.\n\nExclusion Criteria:\n\n* Moderate or severe intellectual disability (IQ less than 70 and those patients in special education classes full time).\n* Schizophrenia or history of any type of psychosis including mood related psychosis and brief reactive psychosis.\n* In custody of Children's Services.","12 Years","17 Years",{"count":95,"type":20},118,[23],"This study outlines a randomized controlled trial evaluating two brief suicide-specific interventions for adolescents aged 12-17 who are hospitalized for suicidal ideation or attempts. Suicide remains a leading cause of death among youth, and many adolescents are discharged from inpatient care without targeted, suicide-focused treatment, contributing to high rates of readmission and ongoing risk. This study seeks to address that gap by comparing the effectiveness of the Collaborative Assessment and Management of Suicidality-Brief Intervention (CAMS-BI) with the Stanley-Brown Safety Planning Intervention (SPI), both delivered as single-session interventions during inpatient hospitalization.\n\nParticipants (N=118) will be randomly assigned to receive either CAMS-BI or SPI. CAMS-BI is a therapeutic, collaborative framework that focuses on identifying and addressing the underlying psychological drivers of suicidality, while SPI is a structured, practical approach that emphasizes immediate safety through coping strategies, support systems, and means restriction. Following the intervention, participants will be monitored for 90 days post-discharge, with follow-ups at 30, 60, and 90 days.\n\nThe primary outcome is the rate of psychiatric readmissions and suicide-related emergency department visits within 90 days of discharge. Secondary outcomes include changes in suicidal ideation, measured by the Beck Scale for Suicide Ideation, and caregiver confidence in managing their child's safety. Additional measures include distress levels, hopelessness, treatment satisfaction, and engagement.\n\nThe study hypothesizes that CAMS-BI will result in lower readmission rates, greater reductions in suicidal ideation, and improved caregiver confidence compared to SPI. Both interventions produce individualized safety or stabilization plans that are shared with patients and caregivers and incorporated into discharge planning to support continuity of care.\n\nSafety protocols are emphasized throughout the study, given the high-risk population. Participants receive standard clinical care, crisis resources, and close monitoring, with procedures in place to address any escalation in suicide risk. Data will be collected using secure systems, and confidentiality will be maintained through de-identification and controlled access.\n\nOverall, this study aims to determine whether a rapid, inpatient, suicide-focused intervention can improve short-term outcomes for high-risk youth and reduce the likelihood of rehospitalization, ultimately informing scalable approaches to suicide prevention in clinical settings.",[99,100,101,26,102],"Suicidal Ideation","Suicide Attempt","Safety Plan","Hopelessness",[104,105,106,107,29,108,109,102],"Youth suicide","Suicide ideation","Suicide attempt","Suicidal behavior","CAMS therapy","Safety plan","2026-06-03",{"date":112,"type":36},"2026-06-04",{"date":79,"type":20},{"date":115,"type":20},"2027-03-01",{"name":117,"class":43},"The Cleveland Clinic",{"id":119,"slug":120,"hasResults":11,"nctId":121,"briefTitle":122,"officialTitle":122,"acronym":123,"eligibilityCriteria":124,"healthyVolunteers":11,"sex":16,"minAge":125,"maxAge":4,"enrollmentInfo":126,"targetDuration":4,"studyType":21,"phases":128,"briefSummary":130,"conditions":131,"keywords":134,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":147},"100638441","phase-3-lumateperone-for-late-life-depression-100638441","NCT07623135","Lumateperone for Late-Life Depression","IRL Grey-C","Inclusion Criteria:\n\n* Age \\>=60\n* Current unipolar non-psychotic major depression determined by SCID-5\n* MADRS score \\>=20 at screening and \\>=18 at baseline\n* Treatment-resistance defined as documented history of non-response to at least two oral medications of adequate dose and duration in this episode or previous episode, OR clinician determination that treatment augmentation is appropriate\n* Currently taking oral antidepressant prescribed at least minimum therapeutic dose and for at least six weeks duration\n* MMSE score of \\>\u002F=24\n\nExclusion Criteria:\n\n* Dementia\n* High risk for suicide, defined as a 4 or 5 on C-SSRS (indicating active suicidal ideation with current or recent intent or plan), and unable to be managed safely in the clinical trial. Urgent psychiatric referral will be made in these cases.\n* High risk alcohol use: defined as a score of 6 or more on the AUDIT-C\n* Medically inappropriate for participation as determined by PIs.","60 Years",{"count":127,"type":20},100,[129],"PHASE3","The purpose of this research study is to examine how well a medication called lumateperone (Caplyta) works to relieve depression in older adults with treatment-resistant depression. Lumateperone (Caplyta) is approved by the U.S. Food and Drug Administration to treat Major Depressive Disorder in adults who are also taking another antidepressant medication. This study will compare lumateperone (Caplyta) to placebo (a sugar pill without medication).",[132,133,26],"Treatment Resistant Depression (TRD)","Late Life Depression (LLD)",[135,136,137,138],"Late life depression treatment","Treatment resistant depression in older adults","major depression","lumateperone","2026-05-28",{"date":110,"type":36},{"date":142,"type":20},"2026-06",{"date":144,"type":20},"2028-06",{"name":146,"class":43},"Eric Lenze",2,{"id":149,"slug":150,"hasResults":11,"nctId":151,"briefTitle":152,"officialTitle":153,"acronym":154,"eligibilityCriteria":155,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":156,"enrollmentInfo":157,"targetDuration":4,"studyType":21,"phases":159,"briefSummary":160,"conditions":161,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":174},"100639056","personalized-pharmaco-lifestyle-interventions-for-severe-mental-illnesses-lifetrain-100639056","NCT07586150","Personalized Pharmaco-Lifestyle Interventions for Severe Mental Illnesses (LIFETRAIN)","Personalised Pharmaco-Lifestyle Interventions for Severe Mental Illnesses Enhanced by Digital Health and Immersive Technologies","LIFETRAIN","Inclusion Criteria:\n\n* Age 18 to 65 years\n* Able and willing to provide written informed consent\n* Diagnosis of schizophrenia, bipolar disorder, or major depressive disorder according to DSM-5-TR, confirmed by M.I.N.I.\n* Female participants of childbearing potential must agree to use an effective method of contraception\n* Stable psychopathology defined as BPRS less than or equal to 41, MADRS less than or equal to 34, and YMRS less than or equal to 25, with stable psychopharmacological treatment for at least 2 weeks\n* Reduced functioning at screening defined as SF-36 score less than or equal to 40\n* If using benzodiazepines, dose less than or equal to 2 mg lorazepam equivalent per day\n* Stable somatic condition for at least 4 weeks\n* For semaglutide treatment: overweight with BMI at least 27 and less than 30 kg\u002Fm² plus at least one weight-related risk condition, or obesity with BMI at least 30 kg\u002Fm²\n* For optional adaptive neurostimulation: MADRS score at least 19\n* Expected ability to comply with study procedures in the investigator's judgment\n\nExclusion Criteria:\n\n* Unable to provide informed consent\n* Current or past neurological disorder or structural brain pathology that may affect study procedures\n* Known intolerance or hypersensitivity to semaglutide\n* Pregnancy or lactation\n* Serious suicidal risk\n* Substance dependence within the last 3 months\n* BMI less than 18.5 kg\u002Fm²\n* eGFR less than 30 mL\u002Fmin\u002F1.73 m²\n* Type 1 diabetes, diabetic ketoacidosis, diabetic retinopathy, or poorly controlled diabetes with recurrent hypoglycemic episodes\n* Pancreatitis, history of pancreatitis, or pancreatic cancer\n* Multiple endocrine neoplasia type 2 or personal\u002Ffamily history of medullary thyroid cancer\n* Pre-existing significant gastrointestinal conditions such as inflammatory bowel disease or gastroparesis\n* Need for acute surgery\n* Other medical condition that may affect study procedures or participant safety\n* For optional adaptive neurostimulation: nonremovable metal in or around the head, known increased intracranial pressure due to infarcts or trauma, professional metal work or prior ocular metal injury, history of rTMS or ECT, or current (es)ketamine treatment","65 Years",{"count":158,"type":20},140,[23],"This randomized, rater-blind, multicenter clinical trial will evaluate whether a personalized pharmaco-lifestyle intervention improves mental functioning in adults with severe mental illness, including schizophrenia, bipolar disorder, or major depressive disorder. Participants will be randomized to either a modular individualized intervention program or a structured psychoeducation control condition. The individualized intervention may include physical exercise, an anti-inflammatory diet, sleep intervention, social prescribing, semaglutide for eligible participants with overweight or obesity, and optional closed-loop transcranial alternating current stimulation for participants with prominent depressive symptoms. The primary outcome is change in the SF-36 Mental Component Summary score from baseline to Month 3.",[162,26,163,164],"Severe Mental Illness","Bipolar Disorder (BD)","Schizophrenia","2026-05-07",{"date":167,"type":36},"2026-05-14",{"date":169,"type":20},"2028-10",{"date":171,"type":20},"2030-12",{"name":173,"class":43},"Ludwig-Maximilians - University of Munich",5,{"id":176,"slug":177,"hasResults":11,"nctId":178,"briefTitle":179,"officialTitle":180,"acronym":4,"eligibilityCriteria":181,"healthyVolunteers":182,"sex":16,"minAge":183,"maxAge":184,"enrollmentInfo":185,"targetDuration":4,"studyType":21,"phases":187,"briefSummary":188,"conditions":189,"keywords":192,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":196,"startDateStruct":198,"completionDateStruct":200,"leadSponsor":202,"locationsCount":84},"100636620","neural-correlates-of-suicidal-behavior-in-youth-100636620","NCT07568054","Neural Correlates of Suicidal Behavior in Youth","Neural Correlates of Suicidal Behavior in Youth: a Pre and Post CAMS Therapy Neuroimaging Study","Inclusion Criteria:\n\n* Subjects must be 14-24 years old\n* Subjects must be:\n\n  * High Risk Subjects: Psychiatrically admitted due to a suicide attempt or history of 2 previous suicide attempts\n  * Medium Risk Subjects: Suicide ideation for the past year with no suicide attempt\n  * Minimal Risk Subjects: No previous history of suicidal ideation or behavior, not taking any psychiatric history or medication, and no family history of suicide\n* Subjects must have the ability to understand and the willingness to sign a written informed consent\u002Fassent document\n* Subjects must be English speaking\n\nExclusion Criteria:\n\n* Subjects with known history of Autism Spectrum Disorder; non-verbal patients\n* Subjects with moderate or severe intellectual disability (IQ less than 70 and those patients in special education classes full time)\n* Subjects with Schizophrenia or history of any type of psychosis including mood related psychosis and brief reactive psychosis\n* Within 6 months before initial screening, urine toxicology positive for phencyclidine, cocaine or amphetamines (subjects prescribed amphetamines for the management of ADHD will not be excluded)\n* Subjects with a history of moderate or severe substance or alcohol use per DSM-5 criteria in the past 6 months\n* Subjects who are currently pregnant or breastfeeding\n* Subjects in custody of Children's Services\n* Subjects with recent bone, tendon, spine or joint surgery\n* Subjects with recent metallic dental implants\n* Subjects weighing less than 30 kg or more than 200 kg",true,"14 Years","24 Years",{"count":186,"type":20},60,[23],"This study, titled \"Neural Correlates of Suicidal Behavior in Youth: a Pre and Post CAMS Therapy Neuroimaging Study,\" aims to better understand the brain mechanisms underlying suicidal thoughts and behaviors in adolescents and young adults (ages 14-24). Suicide is a leading cause of death in this population, and current clinical approaches often fail to accurately predict or prevent suicidal behavior. This study seeks to identify objective neurobiological markers associated with suicide risk and treatment response.\n\nParticipants will be divided into three groups: (1) high-risk individuals recently hospitalized following a suicide attempt, (2) medium-risk individuals with chronic suicidal ideation but no attempts, and (3) low-risk healthy controls. All participants will undergo advanced neuroimaging, including magnetoencephalography (MEG) and magnetic resonance imaging (MRI), along with comprehensive psychiatric assessments.\n\nThe study focuses on brain regions and networks implicated in suicidality, including the anterior cingulate cortex and salience network, as well as neurochemical markers such as glutamate. It also examines electrophysiological activity and functional connectivity patterns associated with suicidal thoughts and behaviors.\n\nHigh-risk participants will receive an evidence-based psychotherapy called the Collaborative Assessment and Management of Suicidality (CAMS). This therapeutic approach emphasizes collaboration between patient and clinician to identify and address the underlying drivers of suicidal thoughts, with a focus on increasing hope and reducing psychological distress. Neuroimaging and clinical assessments will be repeated after completion of CAMS to evaluate treatment-related changes.\n\nThe study's primary goals are to:\n\n* Identify neural and electrophysiological correlates of suicide risk.\n* Distinguish biological differences between individuals with suicidal ideation and those who have attempted suicide.\n* Determine how CAMS therapy affects brain function and neurochemistry.\n\nBy integrating clinical and neurobiological data, this research aims to improve understanding of suicidality, enhance risk prediction, and inform more effective, personalized interventions for at-risk youth.",[99,100,190,26,102,191],"Suicidal Behavior","Neurobiological",[193,106,107,104,29,102,108,194],"Suicidal ideation","Neuroimaging","2026-04-29",{"date":197,"type":36},"2026-05-05",{"date":199,"type":20},"2026-04-13",{"date":201,"type":20},"2031-10-01",{"name":117,"class":43},{"id":204,"slug":205,"hasResults":11,"nctId":206,"briefTitle":207,"officialTitle":207,"acronym":4,"eligibilityCriteria":208,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":125,"enrollmentInfo":209,"targetDuration":4,"studyType":211,"phases":4,"briefSummary":212,"conditions":213,"keywords":4,"overallStatus":215,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":217,"startDateStruct":219,"completionDateStruct":221,"leadSponsor":223,"locationsCount":84},"100374761","brain-imaging-of-cognition-inn-schizophrenia-and-depression-100374761","NCT04159662","Brain Imaging of Cognition Inn Schizophrenia and Depression","Inclusion Criteria:\n\n* age 18-60 years\n* current Intelligence Quotient (IQ) \\> 70 as measured by the Wechsler Abbreviated Scale of Intelligence (WASI)\n* the ability to read and speak fluent English\n* a diagnosis of schizophrenia, schizoaffective or major depression disorder\n* stable medication for more than one month\n\nExclusion Criteria:\n\n* significant neurological or other medical disorders that may produce cognitive impairment\n* a recent history of substance abuse or dependence (within the past 3 months)\n* any magnetic resonance imaging (MRI) contraindications (e.g. metallic head implant, history of seizure, pacemaker)\n* decisional incapacity requiring a guardian\n* taking medications that are rated as Anticholinergic Burden (ACB) Score 3 (severe) or taking benzodiazepines on a daily basis\n* Finally, participants could not be severely symptomatic at the time of study enrolment to ensure that they could understand and complete all study assessments. This criterion was defined as a score ≤34 on the Montgomery-Åsberg Depression Rating Scale (MADRS; Montgomery \\& Åsberg, 1979) for the MDD group and a score ≤95 on the Positive and Negative Syndrome Scale (PANSS; Kay et al., 1987) for the SZ group.",{"count":210,"type":20},90,"OBSERVATIONAL","Schizophrenia and depression are among the most disabling disorders in all of medicine. Cognitive deficits play a key role in patients' disability, affecting their capacity to contribute actively to society by sustaining employment or academic activity. Moreover, cognitive difficulties tend to persist even after the stabilization of other clinical symptoms. Verbal memory and emotion regulation are two important cognitive domains that are impaired in schizophrenia and depression and are associated with patients' functional outcomes. In this study, brain imaging is used to investigate the brain mechanisms underlying these cognitive deficits in these populations.",[214,26],"Schizophrenia \u002F Schizoaffective Disorder","RECRUITING","2026-03-19",{"date":218,"type":36},"2026-03-23",{"date":220,"type":36},"2019-12-12",{"date":222,"type":20},"2026-10-01",{"name":224,"class":43},"The Royal Ottawa Mental Health Centre"]